Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GX301
- Development stage
- Phase 2
- Lead developer
- Mediolanum Farmaceutici
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal, Topical
01
Overview
GX301 is an experimental therapeutic cancer vaccine designed to stimulate the immune system against human telomerase reverse transcriptase (hTERT), a catalytic subunit of telomerase that is overexpressed in most cancers. The vaccine consists of four immunogenic peptides derived from hTERT and two adjuvants (Montanide ISA-51 VG and imiquimod). It aims to induce both CD4+ and CD8+ T cell responses targeting tumor cells expressing telomerase. Clinical studies have shown that GX301 is safe and immunogenic in patients with metastatic castration-resistant prostate cancer, with evidence of robust immune responses. The primary indication under investigation has been prostate cancer, but it has also been studied in renal cell carcinoma[1][2][3][4][7].
- Other names
- telomerase peptide cancer vaccinehTERT multipeptide/Montanide ISA-51 VG/imiquimod vaccine
02
Targets
TERT (Telomerase)CD4 (T lymphocyte surface antigen)γδ TCR (T-cell receptor)MHC II (Major histocompatibility complex class II receptor)MHC I (MHC class I})
Beyond the preview
Go deeper on GX301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GX301.